Attovia Reports Q2 2026 Loss of $20.7M; IPO Proceeds Extend Runway into 2030
ATTO sits 43% above its 52-week low of $16.15 on light trading volume (0.2× avg).
Summary
Attovia Therapeutics reported a $20.7M Q2 net loss and disclosed its August IPO raised $305.4M net, extending cash runway into 2030.
Key Events · Earnings and Guidance · ATTO
-
Q2 Net Loss Widens to $20.7M
Net loss for Q2 2026 was $20.7M, up from $14.4M in Q2 2025, driven by a 39% increase in R&D expenses to $18.9M.
-
IPO Proceeds Extend Runway into 2030
The August 6 IPO raised $332.4M gross ($305.4M net). Combined with $115.1M in cash and securities as of June 30, management projects funding into 2030.
-
Reverse Stock Split and Preferred Conversion
A 1-for-9.29 reverse split was effected July 29, 2026, and all 199.9M preferred shares converted into 21.5M common shares at the IPO closing.
-
Pipeline Progress Drives R&D Spend
Clinical, manufacturing, and preclinical services costs rose 52% to $14.0M in Q2, reflecting advancement of ATTO-1310, ATTO-2306, and ATTO-1091.
Analysis · ATTO · Life Sciences
Attovia's first quarterly report as a public company shows a $20.7M net loss for Q2 2026, up from $14.4M a year earlier, driven by a 39% jump in R&D spending as it advances ATTO-1310, ATTO-2306, and ATTO-1091. The company completed its IPO on August 6, raising $305.4M net, which management says funds operations into 2030. The 1-for-9.29 reverse split and the conversion of all preferred stock into common shares are also disclosed here for the first time.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1944 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATTO was trading at $23.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $16.15 to $24.32. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.